Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 28

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

MiR‐129‐5p promotes docetaxel resistance in prostate cancer by down‐regulating CAMK2N1 expression

Wu, Cheng, Miao, Chunqing, Tang, Qingsheng, Zhou, Xunrong, Xi, Pengshan, Chang, Ping'an, Hua, Lixin, Ni, Haodong·2020·Journal of Cellular and Molecular Medicine

Abstract

This study focuses on the effect of miR‐129‐5p on docetaxel‐resistant (DR) prostate cancer (PC a) cells invasion, migration and apoptosis. In our study, the expression of CAMK 2N1 was assessed by qRT‐PCR in PC a patient tissues and cell lines including PC‐3 and PC‐3‐DR. Cells transfected with miR‐129‐5p mimics, inhibitor, CAMK 2N1 or negative controls (NC) were used to interrogate their effects on DR cell invasions, migrations and apoptosis during docetaxel (DTX) treatments. The apoptosis rate of the PC a cells was validated by flow cytometry. Relationships between miR‐129‐5p and CAMK 2N1 levels were identified by qRT‐PCR and dual‐luciferase reporter assay. CAMK 2N1 was found to be down‐expressed in DR PC a tissue sample, and low levels of CAMK 2N1 were correlated with high docetaxel resistance and clinical prediction of poor survival. CAMK 2N1 levels were decreased in DR PC a cells treated with DXT. We further explored that up‐regulation of miR‐129‐5p could promote DR PC a cells viability, invasion and migration but demote apoptosis. Involved molecular mechanism studies revealed that miR‐129‐5p reduced downstream CAMK 2N1 expression to further impact on chemoresistance to docetaxel of PC a cells, indicating its vital role in PC a docetaxel resistance. Our findings revealed that miR‐129‐5p contributed to the resistance of PC‐3‐DR cells to docetaxel through suppressing CAMK 2N1 expression, and thus targeting miR‐129‐5p may provide a novel therapeutic approach in sensitizing PC a to future docetaxel treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcmm.14050

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Differential expression of CAMK2N1 in prostate cancer resistant cell lines. (A) Heat map of differentially expressed mRNAs in normal and docetaxel‐resistant (DR) cell lines (DU‐145 and PC‐3). The colour gradation indicates the log of fold change (FC) with a base of 2. (B) The relative mRNA expression levels of CAMK2N1 in 18 pairs of docetaxel‐free and DR tissues of prostate cancer patients were detected by qRT‐PCR. Data are expressed as mean ± SD (n = 36). *P < 0.05 compared to the docetaxel‐free group. (C, D) The relative mRNA and protein expression levels of CAMK2N1 in prostate cancer cell line PC‐3 and PC‐3 DR cell line (PC‐3‐DR) were detected by qRT‐PCR and western blot. Data are expressed as mean ± SD (n = 36). **P < 0.01 compared to the PC‐3 group
Figure 1 Differential expression of CAMK2N1 in prostate cancer resistant cell lines. (A) Heat map of differentially expressed mRNAs in normal and docetaxel‐resistant (DR) cell lines (DU‐145 and PC‐3). The colour gradation indicates the log of fold change (FC) with a base of 2. (B) The relative mRNA expression levels of CAMK2N1 in 18 pairs of docetaxel‐free and DR tissues of prostate cancer patients were detected by qRT‐PCR. Data are expressed as mean ± SD (n = 36). *P < 0.05 compared to the docetaxel‐free group. (C, D) The relative mRNA and protein expression levels of CAMK2N1 in prostate cancer cell line PC‐3 and PC‐3 DR cell line (PC‐3‐DR) were detected by qRT‐PCR and western blot. Data are expressed as mean ± SD (n = 36). **P < 0.01 compared to the PC‐3 groupCC BY · PubMed Central
Figure 2 Increased cell viability and decreased apoptosis of PC‐3‐DR cells in docetaxel treatment. (A) Cells were cultured in 10% FBS media treated with different concentrations (from 0 to 80 nmol/L) of docetaxel. IC 50 of docetaxel was determined after 6 days of treatment. Data are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group. (B) Dynamic changes of cell activity during and after docetaxel treatment. 60 nmol/L docetaxel was used. Cell survival rate was measured at days 0, 1, 2, 3, 4 and 5, respectively. Data are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group. (C) Cells were treated with docetaxel (60 nmol/L). Flow cytometry analyses show apoptosis rate in both PC‐3 and PC‐3‐DR cell lines after docetaxel (60 nmol/L) treatment. Data are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group. (D) Transwell assay was performed to detect cell migration and invasion ability after DTX treated for 24 h, scale bar = 50 μm. Results are expressed as mean ± SD (n = 5). *P < 0.05, **P < 0.01 compared to the PC‐3 group
Figure 2 Increased cell viability and decreased apoptosis of PC‐3‐DR cells in docetaxel treatment. (A) Cells were cultured in 10% FBS media treated with different concentrations (from 0 to 80 nmol/L) of docetaxel. IC 50 of docetaxel was determined after 6 days of treatment. Data are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group. (B) Dynamic changes of cell activity during and after docetaxel treatment. 60 nmol/L docetaxel was used. Cell survival rate was measured at days 0, 1, 2, 3, 4 and 5, respectively. Data are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group. (C) Cells were treated with docetaxel (60 nmol/L). Flow cytometry analyses show apoptosis rate in both PC‐3 and PC‐3‐DR cell lines after docetaxel (60 nmol/L) treatment. Data are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group. (D) Transwell assay was performed to detect cell migration and invasion ability after DTX treated for 24 h, scale bar = 50 μm. Results are expressed as mean ± SD (n = 5). *P < 0.05, **P < 0.01 compared to the PC‐3 groupCC BY · PubMed Central
Figure 3 CAMK2N1 inhibited docetaxel resistance in prostate cancer (PCa). (A, B) After CAMK2N1 overexpression vector (pcDNA 3.1‐CAMK2N1) transfection, CAMK2N1 mRNA expression was determined by qRT‐PCR and western blot in PC‐3‐DR cells. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (C) Cell survival rate of PC‐3‐DR treated with DTX was detected by CCK‐8 assay at days 0, 1, 2, 3, 4 and 5, respectively. (D) Apoptotic cell death was measured with flow cytometry analyses after transfection with pcDNA 3.1‐CAMK2N1 and treatment of DTX for 24 h. *P < 0.05, **P < 0.01, ***P < 0.001. (E, F) PCa cells invasion and migration ability were detected after treatment of DTX for 24 h, scale bar = 50 μm. The cell numbers were counted and results are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 group
Figure 3 CAMK2N1 inhibited docetaxel resistance in prostate cancer (PCa). (A, B) After CAMK2N1 overexpression vector (pcDNA 3.1‐CAMK2N1) transfection, CAMK2N1 mRNA expression was determined by qRT‐PCR and western blot in PC‐3‐DR cells. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (C) Cell survival rate of PC‐3‐DR treated with DTX was detected by CCK‐8 assay at days 0, 1, 2, 3, 4 and 5, respectively. (D) Apoptotic cell death was measured with flow cytometry analyses after transfection with pcDNA 3.1‐CAMK2N1 and treatment of DTX for 24 h. *P < 0.05, **P < 0.01, ***P < 0.001. (E, F) PCa cells invasion and migration ability were detected after treatment of DTX for 24 h, scale bar = 50 μm. The cell numbers were counted and results are expressed as mean ± SD (n = 5). **P < 0.01 compared to the PC‐3 groupCC BY · PubMed Central
Figure 4 MiR‐129‐5p targeted CAMK2N1 3′UTR. (A) Base pairing complement suggested the putative miR‐129‐5p binding position at 3′‐UTR of CAMK2N1. (B) Venn diagram displayed miR‐129‐5p shared in the databases of miRDB, microRNA, RNA22v2.0 and TargetScan Human 7.1. (C) Dual‐luciferase reporter assays verified just miR‐129‐5p has the target‐relationship to CAMK2N1 3′UTR. Data are expressed as mean ± SD (n = 3). **P < 0.01 compared to the co‐transfected of wild CAMK2N1 3′UTR vector and transfection reagent group
Figure 4 MiR‐129‐5p targeted CAMK2N1 3′UTR. (A) Base pairing complement suggested the putative miR‐129‐5p binding position at 3′‐UTR of CAMK2N1. (B) Venn diagram displayed miR‐129‐5p shared in the databases of miRDB, microRNA, RNA22v2.0 and TargetScan Human 7.1. (C) Dual‐luciferase reporter assays verified just miR‐129‐5p has the target‐relationship to CAMK2N1 3′UTR. Data are expressed as mean ± SD (n = 3). **P < 0.01 compared to the co‐transfected of wild CAMK2N1 3′UTR vector and transfection reagent groupCC BY · PubMed Central
Figure 5 MiR‐129‐5p promoted the drug resistance of docetaxel in PCa by targeting CAMK2N1. (A) miR‐129‐5p mimics and inhibitors expressed in PC‐3‐DR cells. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (B) Effects of miR‐129‐5p mimics and inhibitors on CAMK2N1 mRNA was detected by qRT‐PCR. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (C) Effects of miR‐129‐5p mimics and inhibitors on CAMK2N1 protein was detected by western blot. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (D) After treated PC‐3‐DR cell with DTX (60 nmol/L) for 24 h, miR‐129‐5p promoted cell survival of PC‐3‐DR while CAMK2N1 inhibited the positive effect of miR‐129‐5p on cell survival. *P < 0.05, compared with MOCK+DTX group. (E) MiR‐129‐5p attenuated apoptosis of PC‐3‐DR while CAMK2N1 promoted cell apoptosis. *P < 0.05, **P < 0.01, compared with MOCK+DTX group; #P < 0.05, compared with mimics+DTX group. (F, G) MiR‐129‐5p facilitated the invasion and migration of PC‐3‐DR while CAMK2N1 impeded the positive effect of miR‐129‐5p on cell invasion and migration, scale bar = 50 μm. *P < 0.05, **P < 0.01, ***P < 0.001 compared with MOCK+DTX group; #P < 0.05, compared with mimics+DTX group
Figure 5 MiR‐129‐5p promoted the drug resistance of docetaxel in PCa by targeting CAMK2N1. (A) miR‐129‐5p mimics and inhibitors expressed in PC‐3‐DR cells. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (B) Effects of miR‐129‐5p mimics and inhibitors on CAMK2N1 mRNA was detected by qRT‐PCR. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (C) Effects of miR‐129‐5p mimics and inhibitors on CAMK2N1 protein was detected by western blot. Data are expressed as mean ± SD (n = 4). **P < 0.01 compared to the control group. (D) After treated PC‐3‐DR cell with DTX (60 nmol/L) for 24 h, miR‐129‐5p promoted cell survival of PC‐3‐DR while CAMK2N1 inhibited the positive effect of miR‐129‐5p on cell survival. *P < 0.05, compared with MOCK+DTX group. (E) MiR‐129‐5p attenuated apoptosis of PC‐3‐DR while CAMK2N1 promoted cell apoptosis. *P < 0.05, **P < 0.01, compared with MOCK+DTX group; #P < 0.05, compared with mimics+DTX group. (F, G) MiR‐129‐5p facilitated the invasion and migration of PC‐3‐DR while CAMK2N1 impeded the positive effect of miR‐129‐5p on cell invasion and migration, scale bar = 50 μm. *P < 0.05, **P < 0.01, ***P < 0.001 compared with MOCK+DTX group; #P < 0.05, compared with mimics+DTX groupCC BY · PubMed Central
Figure 6 CAMK2N1 reversed the effect of miR‐129‐5p on inhibiting activation of ERK/MEK and promoting Bax/Bcl2. (A) Expression levels of CAMK2N1, p‐ ERK1/2, ERK1/2, p‐MEK1, MEK1, Bcl‐2 and BAX were determined by Western blot in PC‐3‐DR cells. *P < 0.05, **P < 0.01, compared with MOCK+DTX group; ##P < 0.01, compared with mimics+DTX group
Figure 6 CAMK2N1 reversed the effect of miR‐129‐5p on inhibiting activation of ERK/MEK and promoting Bax/Bcl2. (A) Expression levels of CAMK2N1, p‐ ERK1/2, ERK1/2, p‐MEK1, MEK1, Bcl‐2 and BAX were determined by Western blot in PC‐3‐DR cells. *P < 0.05, **P < 0.01, compared with MOCK+DTX group; ##P < 0.01, compared with mimics+DTX groupCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 28 references

Cited by

See all 28

Metadata

Authors
Wu, C., Miao, C., Tang, Q., Zhou, X., Xi, P., Chang, P., Hua, L., & Ni, H.
Affiliations
  • Department of Urology The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China
  • Department of Urology People's Hospital of Dongtai City Dongtai Jiangsu China
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2019-12-26
Volume
24
Issue
3
Pages
2098-2108
ISSN
  • 1582-1838
  • 1582-4934
Cited by
28
References
28
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MiR‐129‐5p promotes docetaxel resistance in prostate cancer by down‐regulating CAMK2N1 expression. https://app.cochat.ai/papers/10.1111/jcmm.14050
The paper
Wu, C., Miao, C., Tang, Q., Zhou, X., Xi, P., Chang, P., Hua, L., & Ni, H. (2020). MiR‐129‐5p promotes docetaxel resistance in prostate cancer by down‐regulating CAMK2N1 expression. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.14050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.